Anyone else have this?: There is a monoclonal protein present overlying transferrin in the beta region that measures between 0.8 and 1.3 g/dl with suppression of polyclonal immunoglobulins. Immunofixation electrophoresis is consistent with the previously identified IgA kappa monoclonal gammopathy. The monoclonal protein cannot be accurately measured with this methodology. IFE also shows a small free kappa monoclonal protein (monoclonal protein #2) in the alpha-2 region.
I ask my Dr and am just told the disease is "progressing"?? Since for 10 yrs I've watched the mspike, now not sure how well the meds are working since light chains are very high. Am on dara faspro and Pom this year and not seeing results but have to keep stopping the Pom due to low blood cells...Keep reading about other new meds like Ventaclave, etc?? My beta 2 is very high and i wonder what can bring that down? Thanks and happy holidays.

Your Feed
Filter by
See content from
Playlist: ASH 2023
Use of Biomarkers to Predict CAR-T Outcomes | Darren Pan, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Addressing Racial and Ethnic Disparities in AML Clinical Trials | Andrew Hantel, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Study on Minimizing Exclusion for AML Patients in Clinical Trials | Andrew Hantel, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Results from Venetoclax Added to CLAD Combo for Older Patients With AML | Tapan Kadia, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Moving to a Fully Oral Drug Combination for Older/Frail AML Patients | Tapan Kadia, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Extending AML Remissions with Hypomethylating Agents and Venetoclax | Tapan Kadia, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Effects of Stem Cell Infusion with BCMA CAR-T | Meera Mohan, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Real World Teclistamab Results for Relapsed Refractory Myeloma Patients | Meera Mohan, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Updates to Management of CAR-T and Teclistamab for Myeloma Patients | Radhika Bansal, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
iStopMM Trial in Iceland #myeloma | Jón Þórir Óskarsson, MSc | ASH 2023
Video details & playlist
Playlist: ASH 2023
Impact of Financial Toxicity and Time Toxicity in Myeloma QOL | Rahul Banerjee, MD, FACP | ASH 2023
Video details & playlist
Playlist: ASH 2023
Real-World Bortezomib Patterns in Newly Diagnosed Myeloma | Gurbakhash Kaur, MD, MA | ASH 2023
Video details & playlist
Playlist: ASH 2023
Fine Particulate Matter and Myeloma Outcomes in Urban Cohort | Michael Wysota, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Genomic Profiling in High-Risk Smoldering Myeloma | Benjamin Diamond, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Dexamethasone Dose Strength Impact in Newly Diagnosed Myeloma | Rahul Banerjee, MD, FACP | ASH 2023
Video details & playlist
Playlist: ASH 2023
CAR-T in Myeloma Patients with Extramedullary and Paramedullary Disease | Darren Pan, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Real-World Patient Profile and Dosing of Teclistamab in Myeloma | Carlyn Rose Tan, MD | ASH 2023
Video details & playlist

